GC Biopharma Corp.
Financials
Valuation Metrics
GC Biopharma Corp.'s Market Cap is ₩1.4T. At end of 2025 it was ₩1.9T. Ranked #258 of 2,421 in KR market (top 11%), #196 of 781 on KOSPI (top 25%), #25 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 11%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.42T KRW | KR#258/2,421 Sec#25/231 |
| Revenue | 1.96T KRW | KR#261/2,421 Sec#6/231 |
| Net Income | -63.45B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 2.97T KRW | KR#242/2,421 Sec#8/231 |
| Net Assets | 1.39T KRW | KR#228/2,421 Sec#10/231 |
| Employees | 2,355 | KR#124/2,421 Sec#4/231 |
| Value | ||
| P/B | 1.02x | KR#1,485/2,421 Sec#94/231 |
| P/S | 0.72x | KR#1,161/2,421 Sec#60/231 |
| EV/EBITDA | 47.30x | KR#1,337/2,421 Sec#85/231 |
| FCF Yield | 1.90% | KR#1,059/2,421 Sec#71/231 |
| Profitability | ||
| ROE | -4.55% | KR#1,787/2,421 Sec#128/231 |
| ROA | -2.14% | KR#1,764/2,421 Sec#124/231 |
| Op. Margin | 2.41% | KR#1,327/2,421 Sec#95/231 |
| Revenue Growth | 9.73% | KR#916/2,421 Sec#89/231 |
| Earnings Growth | -205.91% | KR#1,242/2,421 Sec#85/231 |
| Financial Health | ||
| Debt Ratio | 113.09% | KR#1,657/2,421 Sec#189/231 |
| Total Debt | 862.25B KRW | KR#226/2,421 Sec#7/231 |
| FCF | 27.10B KRW | KR#440/2,421 Sec#25/231 |
| Cash | 49.37B KRW | KR#743/2,421 Sec#44/231 |
| Current Ratio | 1.35x | KR#1,327/2,421 Sec#139/231 |
| Net Debt/EBITDA | 17.19x | KR#1,346/2,421 Sec#95/231 |
| Dividend | ||
| Div. Yield | 1.23% | KR#1,061/2,421 Sec#59/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -7.59% | KR#906/2,421 Sec#54/231 |
| 1M Return | 0.66% | KR#1,157/2,421 Sec#87/231 |
| From 52W High | -33.73% | KR#663/2,421 Sec#42/231 |
| 1Y MDD | -37.22% | KR#475/2,421 Sec#36/231 |
| Trading | ||
| Volume | 38,372 shares | KR#1,258/2,421 Sec#124/231 |
| Trading Value | 4.66B KRW | KR#380/2,421 Sec#36/231 |
| Foreign Own. | 23.82% | KR#177/2,421 Sec#8/231 |
| Per Share | ||
| EPS | -5,429 KRW | KR—/2,421 Sec—/231 |
| BPS | 119,306 KRW | KR#120/2,421 Sec#6/231 |
Company Info
Established in 1969 and headquartered in Yongin-si, Gyeonggi-do, Green Cross is a professional pharmaceutical manufacturer and seller specializing in blood products and vaccine products. Its main businesses include blood products, general products, and vaccine products. The company strengthened its raw plasma procurement capabilities by acquiring US ABO Holdings in 2025 and is entering the global market with ALYGLO's US FDA approval and 2024 launch. Green Cross supplies products to domestic and international markets through its Ochang factory production facilities, aiming to become a global pharmaceutical company focused on key strategic products.